Clinical Trial Data Shows Positive Results For Liver Disease Therapy

BioVie Presents Promising Clinical Safety Data from Phase 2b Trial of BIV201.

In a significant breakthrough, BioVie Inc. has presented positive clinical safety data from the Phase 2b trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2023.

The Phase 2b trial of BIV201 aimed to gather preliminary data for the evaluation of the drug's efficacy in reducing asc…